Although the cIMPACT-NOW 3 signature was recommended to refine the classification of IDHwt gliomas, we sought to assess whether it also occurred in cases with IDH1/2 mutations and if it impacts upon prognosis in this subgroup of gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.